Abstract
Angiogenesis is a tightly regulated process that leads to the formation of new blood vessels in limited physiological conditions, and can also occur under pathological situations as retinopathies, arthritis, endometriosis and cancer. Enhanced angiogenesis is present in tumors that need new blood capillaries to grow, remove metabolic waste and transport the cells to locations distal to the primary tumor, facilitating metastasis formation. For these reasons, blockade of angiogenesis is an attractive approach for the treatment of both solid and haematological malignancies. Antiangiogenic therapy should be less toxic in comparison with conventional treatments such as chemotherapy, being angiogenesis a process relatively restricted to the growing tumor. The Src family of tyrosine kinases has been implicated in the intracellular signaling cascade that acts downstream of cell surface receptors to elicit different cellular functions, including growth, proliferation, adhesion and motility. Src kinases are frequently activated in human malignancies, causing tumor progression, metastasis formation and deregulating expression of proangiogenic molecules. This review reports several studies performed by different authors demonstrating the involvement of Src tyrosine kinases in angiogenesis by regulating different signalling pathways. Moreover, we report selective Src inhibitors for which a direct involvement with angiogenesis has been demonstrated, even if every Src inhibitor could potentially possesses also antiangiogenic properties. Biological data, structures and mechanisms of action of selected molecules, in terms of Src protein-inhibitor interactions, are also reported.
Keywords: Angiogenesis, cancer, tyrosine kinase, Src, VEGF, FGF, small molecules inhibitors, binding mode
Current Pharmaceutical Design
Title: Src Inhibitors and Angiogenesis
Volume: 13 Issue: 21
Author(s): S. Schenone, F. Manetti and M. Botta
Affiliation:
Keywords: Angiogenesis, cancer, tyrosine kinase, Src, VEGF, FGF, small molecules inhibitors, binding mode
Abstract: Angiogenesis is a tightly regulated process that leads to the formation of new blood vessels in limited physiological conditions, and can also occur under pathological situations as retinopathies, arthritis, endometriosis and cancer. Enhanced angiogenesis is present in tumors that need new blood capillaries to grow, remove metabolic waste and transport the cells to locations distal to the primary tumor, facilitating metastasis formation. For these reasons, blockade of angiogenesis is an attractive approach for the treatment of both solid and haematological malignancies. Antiangiogenic therapy should be less toxic in comparison with conventional treatments such as chemotherapy, being angiogenesis a process relatively restricted to the growing tumor. The Src family of tyrosine kinases has been implicated in the intracellular signaling cascade that acts downstream of cell surface receptors to elicit different cellular functions, including growth, proliferation, adhesion and motility. Src kinases are frequently activated in human malignancies, causing tumor progression, metastasis formation and deregulating expression of proangiogenic molecules. This review reports several studies performed by different authors demonstrating the involvement of Src tyrosine kinases in angiogenesis by regulating different signalling pathways. Moreover, we report selective Src inhibitors for which a direct involvement with angiogenesis has been demonstrated, even if every Src inhibitor could potentially possesses also antiangiogenic properties. Biological data, structures and mechanisms of action of selected molecules, in terms of Src protein-inhibitor interactions, are also reported.
Export Options
About this article
Cite this article as:
S. Schenone , F. Manetti and M. Botta , Src Inhibitors and Angiogenesis, Current Pharmaceutical Design 2007; 13 (21) . https://dx.doi.org/10.2174/138161207781039580
DOI https://dx.doi.org/10.2174/138161207781039580 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Biomarkers of microRNAs in Gastric Cancer: An Overview from
Diagnosis to Treatment
MicroRNA Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review
Current Medical Imaging Application of Microdialysis in Clinical Pharmacology
Current Clinical Pharmacology From Natural Products to Small Molecule Ketone Histone Deacetylase Inhibitors: Development of New Class Specific Agents
Current Pharmaceutical Design Targeted Drug Delivery to Macrophages in Parasitic Infections
Current Drug Delivery Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews Chemoresistance of Cancer Cells: Oncogenic Mutation of the p53 Tumor Suppressor Gene
Current Signal Transduction Therapy Role of Mechanical Stress in Monocytes / Macrophages: Implications for Atherosclerosis
Current Vascular Pharmacology Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews Editorial [Hot topic: Bisphosphonates and Bone Diseases: Past, Present and Future (Guest Editor: Dominique HEYMANN)]
Current Pharmaceutical Design Stem Cells in Tumour Microenvironment Aid in Prolonged Survival Rate of Cancer Cells and Developed Drug Resistance: Major Challenge in Osteosarcoma Treatment
Current Drug Metabolism Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets Isomers of 4-[<sup>18</sup>F]fluoro-proline: Radiosynthesis, Biological Evaluation and Results in Humans Using PET
Current Radiopharmaceuticals Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets